index - Epidemiology in dermatology and evaluation of therapeutics

DOCUMENTS

95

 

NOTICES

156

 

 

MOTS CLES

Angiotensin receptor blockers Infliximab Sacroiliitis Drug survival Alitretinoin Auto-Diagnostic Pregnancy Arthritis Ankylosing spondylitis Psoriasis Vigibase® Biomédicaments Antibiotic resistance ArtThese Quality of life Atrial fibrillation Placebo Treatment Adverse side effects Abus d'antibiotiques Immunotherapy Albinism Antimicrobiens Prostate cancer COVID-19 Immune-related adverse events Access to care Antibiotics Azathioprine Anxiety Anti-TNF Apre-milast Burden Apremilast Alcohol Drug reaction Biomarkers Epidemiology Bacterial Biologics Acute Myeloid Leukaemia AML Spondylitis Biologic drug Endocrine toxicity Cardiomyopathy Immune checkpoint inhibitors Autoimmunity Glucocorticoids Spondyloarthritis Beta-lactam antibiotics Systematic review Autoimmune diseases Biosimilar Pharmaceuticals Sipuleucel-T Antibiotic misuse Network meta-analysis Anti-Bacterial Agents ASDAS Graft-versus-host disease Stability Etanercept Biological therapy Cancer Biologic therapy Accelerometer Adolescent Méta-Analyse Pharmaco-Épidémiologie BTK protein Ustekinumab Angiotensin-converting enzyme inhibitors Addiction Atopic dermatitis Management Ethics Axial spondyloarthritis Pharmacovigilance Amyloidosis Biologic Cardio-oncology Dermatology Psoriatic arthritis Pharmacoepidemiology Aging Anti-HCV Direct Acting Antivirals DAA Antimicrobial resistance Antimicrobial Stewardship Anxiété Biological Therapy Intensive care Arrhythmia Adalimumab Anticancer drugs Ankylosing Antimicrobials Cardiotoxicity Bacterial rhinosinusitis Primary adrenal insufficiency Auto-immune hepatitis Meta-Analysis

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS